Ghella renews its commitment alongside Fondazione Umberto Veronesi ETS in support of pediatric oncology research

We firmly believe that a better world is built through small acts of responsibility toward others. It is with this awareness that, also for 2026, we confirm our commitment to supporting Fondazione Veronesi.

For years we have stood alongside the Foundation, sharing values and goals linked to scientific progress in the field of health and medicine. In 2025, our contribution focused on supporting the innovative PALM Research Project® platform, an international network dedicated to developing new treatments for pediatric acute myeloid leukemia.

Within this framework, a result of extraordinary significance was achieved: three young patients affected by acute myeloid leukemia—a particularly aggressive form resistant to conventional therapies—were successfully treated using a new CAR-T cell therapy, achieving complete remission. This represents one of the first uses worldwide of this technology for this disease in pediatric patients, developed at the Bambino Gesù Pediatric Hospital in collaboration with leading Italian research centers, all part of the platform funded by Fondazione Veronesi.

The project marks a significant step forward toward increasingly effective and personalized treatments, with the aim of offering new therapeutic options to patients who currently do not respond to available therapies.

Investing in medical-scientific research means turning innovation into concrete opportunities for care. Because caring for the youngest means giving them a future, even when prospects seem most challenging.

In 2026, we will continue to support Fondazione Veronesi, specifically in pediatric oncology, through a European multicenter study on high-risk neuroblastoma, once again coordinated by the Bambino Gesù Pediatric Hospital in Rome.